Notícias

Pfizer stock slipped after Q1 results despite an earnings beat as investors weighed falling COVID sales and looming patent expirations.

ETFs like XLV stand out as aging U.S. demographics fuel rising demand for healthcare, medical devices and senior-focused care.

Novo Nordisk stock jumps 21% in a month after a Q1 beat and stronger GLP-1 demand, but pricing pressure and Eli Lilly rivalry still cloud its 2026 outlook.

PRTA posted a Q1 profit as a $50M Novo Nordisk milestone payment boosted revenue and improved its 2026 cash outlook.

Novo's price cuts lifted Wegovy and Ozempic demand while cheaper GLP-1 therapies expanded India's obesity-drug market.

Novo now expects profit and sales declines of up to 12% this year, better than its earlier 13% forecast.

Novo Nordisk (NYSE:NVO) raised its 2026 full year guidance after the launch of its oral Wegovy weight loss pill in the U.S. Prescriptions for the oral version have surpassed 2,000,000 since January, signaling strong demand for the new format. The update comes during a period of intense competition with Eli Lilly and ongoing pricing pressures in the weight loss drug market. Novo Nordisk, trading at $45.76, sits at the center of the current weight loss drug story, with oral Wegovy adding a...

Most weight-loss stocks are built on future expectations. Eli Lilly is built on current earnings and expanding demand.

The pill era has ushered in a Wild-West-style land-grab for GLP-1 market share but the horizon seems to keep expanding.

Lilly surges after a Q1 beat and higher guidance, as Mounjaro and Zepbound fueled 56% revenue growth.

Shares of Novo Nordisk (NVO), the maker of the GLP-1 drug Wegovy, popped this morning after the company reported strong demand for its new weight-loss pill.Novo Nordisk President & CEO Mike Doustdar joined Julie Hyman on Opening Bid to discuss Q1 sales and the rest of the year guidance.

The Danish drugmaker is riding a wave of peptide craziness as its weight loss tablet crushes its U.S. debut.

Novo Nordisk (NYSE:NVO) reported first-quarter results that far exceeded analyst estimates on Wednesday, driven by surging demand for its oral weight-loss pill and strong international sales. Net sales reached $15.2 billion in the quarter, well above the $11.2 billion analysts had...

Novo Nordisk stock jumped early Wednesday on a strong first-quarter report on the back of its GLP-1 drugs Wegovy and Ozempic.

First-quarter sales of the oral Wegovy pill hit $353 million, more than double analyst expectations, as the company lifted its full-year outlook

Total prescriptions for the new Wegovy pill reached around 1.3 million in the first quarter and have exceeded 2 million since it launched.

Shares in Wegovy maker Novo Nordisk surged this morning after it reported strong demand for its new weight-loss pill and upgraded its guidance. The Danish drugmaker said total prescriptions for the Wegovy pill reached around 1.

Total prescriptions for the Wegovy pill reached around 1.3 million in the first quarter and have exceeded 2 million since it launched.

COPENHAGEN, May 6 () - Novo Nordisk, the maker of weight-loss drug Wegovy, on Wednesday reported first-quarter revenue and adjusted operating profit above expectations and said its outlook ‌for the year was slightly improved. The Danish drugmaker is banking on demand for ‌its new weight-loss pill as competition with U.

These stocks have been struggling over the past year, but their growth days are far from over.

CPRX's Q1 earnings are expected to beat estimates on strong Firdapse demand and rising Agamree sales, while Fycompa faces patent-driven pressure.

Is NVO a good stock to buy? We came across a bullish thesis on Novo Nordisk A/S on Unfair Advantage’s Substack by AK. In this article, we will summarize the bulls’ thesis on NVO. Novo Nordisk A/S’s share was trading at $38.52 as of April 23rd. NVO’s trailing and forward P/E were 10.65 and 11.38 respectively according […]

Novo Nordisk (CPSE:NOVO B) is rolling out its oral Ozempic (semaglutide) tablet across the US as the only FDA approved oral GLP-1 for adults with type 2 diabetes. The company plans broad distribution through more than 70,000 US pharmacies. New access partnerships with WW International and GoodRx aim to support patients through digital health tools, discounts and self pay options. The launch includes a mix of insurance coverage pathways and cash pay programs targeting both insured and self...

ZTS eyes a Q1 beat as companion animal products and international growth offset U.S. weakness ahead of its May 7 earnings report.